Rituximab may affect T lymphocyte subsets balance in primary membranous nephropathy

被引:1
|
作者
Zhang, Yuanyuan [1 ,2 ]
Yang, Jingjing [3 ]
Li, Jianzhong [1 ]
Sun, Jiani [1 ]
Zhou, Ling [1 ]
Xu, Deyu [1 ]
Sha, Wengang [1 ]
Dai, Lan [4 ]
Shen, Lei [1 ]
机构
[1] Soochow Univ, Dept Nephrol, Affiliated Hosp 1, Suzhou, Peoples R China
[2] Nanjing Univ, Suzhou Hosp, Affiliated Hosp, Dept Nephrol,Med Sch, Suzhou, Peoples R China
[3] BenQ Med Ctr, Dept Nephrol, Suzhou, Peoples R China
[4] Soochow Univ, Jiangsu Inst Hematol, Minist Hlth, Key Lab Thrombosis & Hemostasis,Affiliated Hosp 1, Suzhou, Peoples R China
关键词
Rituximab; Primary membranous nephropathy; T lymphocyte subsets; B lymphocyte cells; Anti-PLA2R antibody; RECEPTOR; CHILDREN; CELLS;
D O I
10.1186/s12882-024-03521-1
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe aim of this study was to investigate the effects and significance of rituximab (RTX) on the levels of T lymphocyte subsets in patients diagnosed with primary membranous nephropathy (PMN).MethodsA total of 58 PMN patients and 25 healthy donors were chosen as the subjects. Among the PMN patients, 40 individuals received RTX treatment and completed at least 6 months of follow-up. All subjects underwent flow cytometry analysis to determine the peripheral blood lymphocyte subsets. The changes in anti-PLA2R antibody titers and 24-hour urinary protein levels were evaluated by ELISA and Biuret method before and after treatment.Results(1) The PMN group exhibited a significantly greater percentage of peripheral blood CD3-CD19+ B cells than the healthy group, which is consistent with the findings of previous reports. Additionally, compared with those in the peripheral blood of healthy individuals, the numbers of CD4+ central memory T cells, CD4+ effector memory T cells, CD4+/CD8+, and CD4+CD25+ T cells in the PMN peripheral blood were markedly greater. However, the number of peripheral blood Treg cells was reduced in the PMN group. (2) After 6 months of RTX treatment, PMN patients exhibited significant decreases in anti-PLA2R antibody titers, 24-hour urinary protein levels, and peripheral blood CD3-CD19+ B cells. Importantly, RTX administration decreased CD4+CD25+ T cells and CD4+/CD8+ in the peripheral blood of PMN patients and improved Treg cell levels. (3) RTX treatment induced alterations in the CD4+ T lymphocyte subsets in PMN patients, which did not correlate with B lymphocyte counts or anti-PLA2R antibody titers.ConclusionsRTX treatment might have a beneficial impact on cellular immunity by effectively restoring the balance of CD4+ T lymphocyte subsets in PMN patients, which is beyond its effects on B cells and antibody production.Trial registrationThe research was registered at the First Affiliated Hospital of Soochow University. Registration Number: MR-32-23-016211. Registration Date: May 31, 2023.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] A Comparative Analysis of Efficacy of Rituximab in Patients with Primary Membranous Nephropathy
    Zhang Qianwei
    Xie Liyi
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [12] Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
    Xu, Mingyue
    Wang, Yifeng
    Wu, Meihe
    Chen, Ruiying
    Zhao, Wenqian
    Li, Mingxin
    Hao, Chuan-Ming
    Xie, Qionghong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024,
  • [13] LYMPHOCYTE-T AND LYMPHOCYTE-B SUBSETS IN FENOPROFEN NEPHROPATHY
    STACHURA, I
    JAYAKUMAR, S
    BOURKE, E
    AMERICAN JOURNAL OF MEDICINE, 1983, 75 (01): : 9 - 16
  • [14] VARIATIONS IN LYMPHOCYTE-T SUBSETS IN IGA NEPHROPATHY
    SANNA, M
    PISTIS, R
    FAEDDA, R
    SATTA, A
    SULIS, E
    SERRA, G
    VARGIU, G
    BARTOLI, E
    CURRENT THERAPY IN NEPHROLOGY, 1989, 24 : 59 - 61
  • [15] Belimumab and Rituximab for the Treatment of Primary Membranous Nephropathy: Initial REBOOT Results
    Nachman, Patrick H.
    Stelzig, Lia
    Sherman, Matthew A.
    Barry, William T.
    Chung, Sharon
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [16] Rituximab in primary membranous nephropathy: a comparative study of three dosing regimens
    Ramachandran, Raja
    Nayak, Saurabh
    Kumar, Vinod
    Sethi, Jasmine
    Minz, Ranjana
    Kumar, Vivek
    Rathi, Manish
    Kohli, Harbir Singh
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36 (07) : 1352 - 1354
  • [17] Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?
    Cravedi, Paolo
    Remuzzi, Giuseppe
    Ruggenenti, Piero
    NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4): : 261 - 269
  • [18] RITUXIMAB IN THE TREATMENT OF PRIMARY MEMBRANOUS NEPHROPATHY - A COMPARATIVE STUDY OF THREE REGIMEN
    Kohli, Harbir Singh
    Ramachandran, Raja
    Rathi, Manish
    Minz, Ranjana
    Duseja, Ritambhra Nada
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 280 - 280
  • [19] Different Dosage Regimens of Rituximab in Primary Membranous Nephropathy Treatment: A Systematic Review
    Yu, Yi
    Xu, Ricong
    Li, Zhijian
    Wan, Qijun
    INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2024, 17 : 265 - 273
  • [20] T lymphocyte subsets in primary antiphospholipid syndrome
    Tommasino, C
    Fossati, G
    Lopez, LR
    Matsuura, E
    Margarita, A
    Scenna, G
    Brancaccio, V
    Ames, PRJ
    THROMBOSIS RESEARCH, 2004, 114 (5-6) : 612 - 612